NPS Pharmaceuticals (NPSP) On Watch With FDA Briefing Documents Posted
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Join SI Premium – FREE
Shares of NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) are on watch with FDA briefing documents posted for the October 16, 2012 Gastrointestinal Drugs Advisory Committee meeting to review Gattex.
FDA staff supports risk plan, says Gattex deemed to work.
The Prescription Drug User Fee Act (PDUFA) date for completion of the review of the company’s New Drug Application (NDA) for Gattex is December 30, 2012.
FDA staff supports risk plan, says Gattex deemed to work.
The Prescription Drug User Fee Act (PDUFA) date for completion of the review of the company’s New Drug Application (NDA) for Gattex is December 30, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Scorpion Capital says short Twist Biosciences
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
